BCTX News and Press, BriaCell Therapeutics Corp. From 02/16/22

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 16, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for ad...

BriaCell Therapeutics (NASDAQ:BCTX) announced on Thursday that the company was selected to perform a presentation on off-the-shelf cancer therapies at the American Association for Cancer Research (AACR) Annual Meeting 2022, scheduled to be held in April. The presentation titled, “Towar...

BriaCell selected to present at the American Association for Cancer Research (AACR) Annual Meeting 2022 Corporate buyback program continues; 1,031,672 shares and 200,740 warrants repurchased since program commencement Insiders intend to acquire up to approxim...

NEW YORK and VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , is pleased to announce that all resolutions proposed to shareholders at the Annual and Spe...

BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 29, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies fo...

BriaCell Therapeutics (NASDAQ:BCTX) is trading ~12.9% higher in the pre-market after announcing that certain members of its board of directors and management team have informed their plans to purchase nearly 10% of the company’s common stock. The insiders intend to use their personal f...

Calliditas Therapeutics (NASDAQ:CALT) +38% on FDA approval for kidney disease therapy. Kaixin Auto (NASDAQ:KXIN) +27% on a partnership agreement with Bujia for 10k new energy trucks. Biomerica (NASDAQ:BMRA) +18% preliminary second quarter revenue increase of approxima...

Insiders intend to acquire up to approximately 10% of BriaCell’s basic common shares, or 1.59 million shares Corporate buyback program will continue; 501,703 shares and 143,236 warrants repurchased since program commencement $5.1 million procee...

Gainers: Petros Pharmaceuticals (NASDAQ:PTPI) +37%, Biofrontera BFRI +20%, ABVC BioPharma (NASDAQ:ABVC) +12%, Halozyme Therapeutics (NASDAQ:HALO) +11%, Context Therapeutics CNTX +9%. Losers: Angion Biomedica (NASDAQ:ANGN) -22%, Ensysce Biosciences ...

Shares of BriaCell (BCTX -9.4%) are down today despite presenting mid-stage data on its breast cancer candidate BRIA-IMT in combination with immune checkpoint inhibitors. Phase 1/2a results presented at the San Antonio Breast Cancer Symposium showed that disease control was 25% and 30% in two...